Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin versus atorvastatin for proteinuria in hypercholesterolaemic non-diabetic adults with moderate proteinuria
2005-002508-41Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rosuvastatin and atorvastatin in hypercholesterolemia and proteinuria (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in urinary protein/creatinine ratio from baseline to Week 52. Started Nov 2005; status: completed.
02
Drugs
rosuvastatinatorvastatin
03
Conditions
hypercholesterolemiaproteinuria
Beyond the preview
Go deeper on 2005-002508-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002508-41.